Abstract
Implantable cardioverter defibrillators (ICDs) have proven highly successful in the treatment of life-threatening ventricular arrhythmias. Despite the efficacy of the ICD in terminating ventricular arrhythmias, antiarrhythmic drugs remain an important adjunct to ICD therapy. The use of antiarrhythmic drug therapy in combination with the ICD is synergistic in terms of beneficial effects, but also has the potential for some adverse interactions. Knowledge and recognition of these potential interactions is important for any physician managing patients with an ICD. This review summarizes the benefits and adverse effects of ICD in combination with antiarrhythmic drug therapy, and provides guidelines to ensure safe application of this hybrid therapy.
Similar content being viewed by others
References and Recommended Reading
Shah B, Russo A, Kuntz C, et al.: Changing patterns in antiarrhythmic drug use in implantable cardioverter defibrillator patients over the last decade [abstract]. PACE 2001, 24:649.
Sperry RE, Stambler BS, Wood M, et al.: Reduction of antiarrhythmic drug use in patients receiving implantable cardioverter defibrillators. PACE 1996, 19:61–64.
Movsowitz C, Marchlinski F: Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol 1998, 82:41I-48I. This paper gives an excellent review of interactions between ICDs and class III agents.
Knilans TK, Prystowsky EN: Antiarrhythmic drug therapy in the management of cardiac arrest survivors. Circulation 1992, 85:I118.
Manz M, Jung W, Luderitz B: Interaction between drugs and devices: experimental and clinical studies. Am Heart J 1994, 127:978.
Greene HL: Interaction between pharmalogical and nonpharmalogical antiarrhythmic therapy. Am J Cardiol 1996, 78:61–66.
Echt D, Armstrong K, Schmidt P, et al.: Clinical experience, complications, and survival in 70 patients with automatic implantable cardioverter-defibrillator. Circulation 1985, 71:289–296.
Bardy GH, Troutman C, Poole JE, et al.: Clinical experience with a tiered therapy multiprogrammable antiarrhythmia device. Circulation 1992, 85:1689–1698.
Epstein AE, Ellenbogen KA, Kirk K, et al., and the high defibrillation threshold investigators: Clinical characteristics and outcome of patients with high defibrillation thresholds. Circulation 1992, 86:1206–1216.
Steinberg JS, Martins J, Sadanandan S, et al.: The AVID Investigators: antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001, 142:520–529. An important prospective study investigating the need for, and effects of, concomitant antiarrhythmic drugs with the ICD.
Gradaus R, Fiseifis F, Huber H, et al.: Mortality, morbidity, and complications in 3344 patients with implantable cardioverter-defibrillators: result from the Germany ICD registry EURID [abstract]. Circulation 2001, 104(Supp II):3098.
Zado E, Deely M, Jumper C, Marchlinski F: Symptoms after ICD discharge: correlation to symptoms before discharge and number of shocks [abstract]. PACE 1999, 2:152.
Exner D, Schron E, Yao Q, et al.: Defibrillator shocks and self-perceived quality of life in the antiarrhythmics versus implantable defibrillators (AVID) trial [abstract]. J Am Coll Cardiol 2000, 35:891–894.
Dunbar S, Zhang Z, Smith P: Quality of life outcomes for ventricular arrhythmia patients: the PRIDE Study. Circulation 2001, 104:(Supp II):3618.
Dougherty CM: Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart Lung 1995, 24:281–291.
Pacifico A, Hohnloser SH, Williams JH, et al., for the d, l-Sotalol Implantable Cardioverter-Defibrillator Study Group. Prevention of implantable-defibrillator shocks by pretreatment with sotalol. N Engl J Med 1999, 340:1855. An important double-blind study that assessed the value of sotalol treatment for the prevention of ICD shocks and improvement of survival.
Kuhlkamp V, Mewis C, Mermi J, et al.: Suppression of sustained ventricular tachyarrhythmias: a comparison of d, I-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999, 33:46–52.
O’Toole M, O’Neill G, Kluger J, et al.: Efficacy and safety of oral dofetilide in patients with an implantable defibrillator: a multicenter study [abstract]. Circulation 1999, 100:I-794.
Dorian P, Newman D: Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993, 72:72A-79A.
Dorian P, Wang M, David I, Feindel C: Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation 1991, 83:614–621.
Dorian P, Newman D, Sheahan R, et al.: d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy. J Cardiovasc Electrophysiol 1996, 7:952–961.
Wang M, Dorian P: DL and D sotalol decrease defibrillation energy requirements. PACE 1989, 12:1522–1529.
Qi X, Newman D, Dorian P: Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Intervent Cardiac Electrophysiol 1999, 3:61–67.
Woolfolk DI, Chaffee WR, Cohen W, et al.: The effect of quinidine on electrical energy required for ventricular defibrillation. Am Heart J 1966, 72:659–663.
Babbs CF, Yim GKW, Whistler SJ, et al.: Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Hear J 1979, 98:345–350.
Dawson AK, Steinberg MI, Shapland JE, et al.: Effects of class I and class II drugs on current and energy required for internal defibrillation. Circulation 1985, 72:384.
Echt DS, Black JN, Barbey JJ, et al.: Evaluation of an antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation. Circulation 1989, 79:1106–1117.
Ware DL, Atkinson JB, Brooks MJ, et al.: Ventricular defibrillation in canines with chronic infarction, and effects of lidocaine and procainamide. PACE 1993, 16:337–346.
Echt DS, Gremillion ST, Lee JT, et al.: Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol 1994, 5:752–760.
Dorian P, Fain ES, Davy JM, et al.: Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol 1986, 8:327–332.
Topham S, Cha YM, Peters BB, et al.: Effects of lidocaine on relation between defibrillation threshold and upper limit of vulnerability in open-chest dogs. Circulation 1992, 85:1146–1151.
Senatore G, Coltorti F, Giordano B, Nocerino P, Stabile G, Simone A, Caprioli V, Chiariello M: Defibrillation threshold in patients with ICD and concomitant antiarrhythmic therapy [abstract]. PACE 1999, 22:413.
Szabo T, Jones D, McQuinn R, Klein G: Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs. J Cardiovasc Pharmacol 1988, 12:377–383.
Natale A, Jones D, Kleinstiver P, et al.: Effects of flecainide on defibrillation threshold in pigs. J Cardiovasc Pharmacol 1993, 21:573–577.
Hernandez R, Mann DE, Breckinridge S: Effects of flecainide on defibrillation threshold in the anesthetized dog. J Am Coll Cardiol 1989, 14:777–781.
Ujhelyi M, O’Rangers E, Kluger J, et al.: Defibrillation energy requirements during moricizine and moricizine-lidocaine therapy. J Cardiovasc Pharmacol 1992, 20:932–939.
Avitall B, Hare J, Zander G, et al.: Cardioversion, defibrillation and overdrive pacing of ventricular arrhythmias: the effect of moricizine in dogs with sustained monomorphic ventricular tachycardia. PACE 1993, 16:2092–2097.
Stevens S, Haffajee C, Naccarelli G, et al.: Effect of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 1996, 28:418–422.
Bailey WM, Fukaye E, Weinberger J, et al.: MK-499, a new class III agent, reduces defibrillation threshold in patients with chronically implanted defibrillators [abstract]. PACE 1995, 18:835.
Gremillion ST, Echt DS, Smith NA, et al.: Beneficial effect of intravenous dofetilide in patients undergoing ventricular defibrillation testing [abstract]. Circulation 1992, 86:I-264.
Fain ES, Lee JT, Winkle RA: Effect of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J 1987, 114:8–17.
Kopp D, Kall J, Kinder C, et al.: Effect of amiodarone and left ventricular mass on defibrillation energy requirements: monophasic versus biphasic shocks [abstract]. PACE 1995, 18:872.
Haberman RJ, Veltri EP, Mower MM: The effect of amiodarone on defibrillation threshold. J Electrophysiol 1998, 2:415–423.
Jung W, Manz M, Pizzulli L, et al.: Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992, 70:1023–1027.
Manz M, Jung W, Luderitz B: Interaction between drugs and device: experimental and clinical studies. Am Heart J 1994, 127(Suppl):978–984.
Frame L: The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implantable electrodes in dogs. PACE 1989, 12:339–346.
Klein RC, Gold M, Higgins S, et al.: The low energy safety study: Baseline characteristics and results of defibrillation testing. Circulation 2001, 104(Supp II):3091.
Zhou l, Chen B, Kluger J, et al.: Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998, 31:1672–1678.
Hook BG, Perlman RL, Callans DJ, et al.: Acute and chronic cycle length dependent increase in ventricular pacing threshold. PACE 1992, 15:1437–1444.
Hellestrand KJ, Nathan AW, Bexton RS, et al.: Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections and pacemakers thresholds. Am J Cardiol 1984, 53:30B-38B.
Marchlinski FE, Buxton AE, Kindwall KE, et al.: Comparision of individual and combined effects of procainamide and amiodarone in patients with sustained ventricular tachyarrhythmias. Circulation 1988, 78:583–591.
Grimm W, Cho JG, Marchlinski FE: Effects of incremental doses of procainamide in patients with sustained uniform ventricular tachycardia. J Card Electrophysiol 1994, 5:313–322.
Farre J, Grande A, Albo PS, et al.: Arrhythmogenic effects of antiarrhythmic drugs in patients with an old myocardial infarction and asymptomatic ventricular ectopic activity as studied by programmed electrical stimulation. Eur Heart J 1987, 8(Suppl A):113–119.
Wellens HJJ, Brugada P, Farre J: Ventricular arrhythmias: mechanism and actions of antiarrhythmic drugs. Am Heart J 1984, 107:1053–1057.
Mazur A, Anderson M, Bonney S, Roden D: Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide. J Am Coll Cardiol 2001, 37:1100–1105.
Johnson N, Marchlinski FE: The need to enhance diagnostic specificity to avoid device response to supraventricular rhyyhms and risk of induced ventricular arrhythmias. J Am Coll Cardiol 1991, 18:1418–1422.
Marchlinski FE, Zado E, Callans DJ, et al.: Hybrid therapy for ventricular arrhythmia management. In Cardiology Clinics: Ventricular Arrhythmias. Edited by Miller JM. Philadelphia: WB Saunders; 1999:391–406.
Wilbur SL, Marchlinski FE: Implantable cardioverterdefibrillator follow-up: what every physician should know. Cardiol Rev 1999, 7:9. This review summarizes routine device follow-up, provides instructions regarding emergency ICD deactivation, and discusses common complications and how to detect them.
Lindsay B: Troubleshooting new ICD system. J Intervent Cardiol 1994, 7:473–485.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rajawat, Y.S., Dias, D., Gerstenfeld, E.P. et al. Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation. Curr Cardiol Rep 4, 434–440 (2002). https://doi.org/10.1007/s11886-002-0044-2
Issue Date:
DOI: https://doi.org/10.1007/s11886-002-0044-2